peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Correction: Hansa Biopharma: increase in number of shares and votes

3 May 2024, 11:11
Regulatory information

The correction only concerns the removal of the reference to the EU Market Abuse Regulation that was incorrectly included in the original press release, distributed at 8:00am CEST on May 03, 2024, and inclusion of reference to the Swedish Financial Instruments Trading Act (1991:980).

Lund, Sweden May 3, 2024. Hansa Biopharma AB (publ), (“Hansa” or the “Company”) (Nasdaq Stockholm: HNSA) today announced that the company’s registered share capital and number of shares and votes have increased through the issue of 10,474,740 new ordinary shares on 12 April 2024, whereby the number of votes increased with 10,474,740 and the share capital increased with SEK 10,474,740.

As of today, the total number of registered shares of the company amounts to 65,508,981, whereof 63,146,536 are ordinary shares and 2,362,445 are class C shares. As of today, the number of votes in the company amounts to 63,382,780.5, and the registered share capital amounts to SEK 65,508,981.

This disclosure contains information that Hansa Biopharma AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact person, on May 3, 2024 at 08:00 CEST.

--- ENDS ---

Contacts for more information:

Evan Ballantyne, Chief Financial Officer

Stephanie Kenney, VP Global Corporate Affairs

About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at